Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Every nine seconds, one person dies as a result of complications from diabetes mellitus (DM), totalling approximately 3.4 million deaths in 2024. These figures reflect not only the global magnitude of this chronic disease but also the devastating impact of its complications, among which diabetic kidney disease (DKD) stands out as one of the most severe and silent microangiopathic manifestations of DM. Photobiomodulation (PBM), characterized as a method of low-intensity light to modulate biological processes, has emerged as a promising intervention. Recent studies have shown that PBM can exert antioxidant, anti-inflammatory, and biostimulatory effects through the modulation of the mitochondrial respiratory chain and nitric oxide (NO) metabolism, which are central factors in the pathophysiology of DKD. Aims/hypothesis: This study aimed to evaluate the effects of photobiomodulation (PBM) on function, oxidative profile, inflammatory profile, renal hemodynamics and histology in rats with DKD.
Methods: Adult male Wistar rats, 250–290 g, were randomized into four groups: Citrate: healthy animals (0.01M citrate buffer); Citrate + PBM (irradiation, 808 nm wavelength; 100 mW power; 3 Joules energy; 30.48 J/cm² fluence; 1 point on the right flank and 1 point on the left flank; 3 times/week; 6 weeks): citrate animals that, on the third day, underwent to PMB ; Diabetes Mellitus (DM): animals that received streptozotocin (STZ; 60 mg/kg; i.v.; once; diluted in 0.1M citrate buffer; pH 4.2; on the first day of the experimental protocol); DM + PBM: DM animals subjected to PBM. The protocol lasted 45 days, during which the animals were monitored for the development of DM and other biological parameters. At the end of this period, physiological parameters, renal function, renal hemodynamics, oxidative and inflammatory profile were assessed.
The results demonstrated a reduction in GFR and an increase in serum creatinine (SCr) levels in the diabetic groups, indicating a decline in renal function associated with sustained hyperglycemia. Diabetic animals treated with photobiomodulation showed a significant reduction in blood glucose levels and a statistically significant improvement in renal function and hemodynamics and reduced inflammatory profile. This was evidenced by an increase in glomerular filtration rate (GFR), a decrease in mean arterial pressure and renal vascular resistance and an increase in renal blood flow. Additionally, a significant reduction in oxidative profile and inflammatory markers were reduced when compared to the untreated diabetic group. Histopathology revealed preservation of the tubulointerstitial compartment in non-diabetic animals, whereas the DM group showed a significant increase in lesion score, but without relevant differences between DM and DM+Fbm.
The findings of this study demonstrate that PMB therapy exerts beneficial effects on renal function and hemodynamics in a model of DKD, possibly mediated by the modulation of oxidative stress, the reduction of pro-inflammatory markers, and partial glycemic control. Taken together, these results support the potential use of photobiomodulation as a non-pharmacological and renoprotective therapeutic strategy in the DKD.
